Moti Ramgopal
A5069170911- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Hepatitis C virus research
- Pharmacological Effects and Toxicity Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
- Hepatitis B Virus Studies
- Mosquito-borne diseases and control
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Infectious Diseases and Tuberculosis
- Infective Endocarditis Diagnosis and Management
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Streptococcal Infections and Treatments
- Tuberculosis Research and Epidemiology
- COVID-19 Clinical Research Studies
- Mycobacterium research and diagnosis
- Actinomycetales infections and treatment
- T-cell and B-cell Immunology
- Respiratory viral infections research
- Virus-based gene therapy research
- Diabetes and associated disorders
Midway University
2016-2025
Florida State University
2014-2025
Emory University
2024
Johns Hopkins University
2024
Grady Memorial Hospital
2024
Brown University
2023
Martin Health System
2014-2021
Janssen (Belgium)
2019
University of Georgia
2016
University of South Florida
2015
The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on safety this coinfected human immunodeficiency type 1 (HIV-1).This was an open-label study involving 151 who had not received treatment 52 previously treated patients, all whom were HIV-1. Previously untreated randomly assigned 2:1 ratio to receive either 12 weeks or 8 daclatasvir at standard dose 60 mg daily...
Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is single-arm, open-label III which therapy-experienced adults with received DTG BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after was optimized ≥1 fully active drug and continued. primary efficacy...
ABSTRACT A small pool of infected cells persists in HIV-infected individuals receiving antiretroviral therapy (ART). Here, we developed ultrasensitive assays to precisely measure the frequency harboring total HIV DNA, integrated and two long terminal repeat (2-LTR) circles. These are performed on cell lysates, which circumvents labor-intensive step DNA extraction, rely coquantification each molecular form together with CD3 gene sequences input. Using primary isolates from subtypes A, B, C,...
Background: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared TDFcontaining regimens.We report the 48 week efficacy of once-daily single tablet regimen elvitegravir 150 mg (E), cobicistat (C), emtricitabine 200 (F), TAF 10 (E/C/F/TAF) in HIV-1-infected patients mild to moderate impairment. Methods:We enrolled virologically suppressed subjects estimated creatinine clearance (CrCl) 30-69 mL/min single-arm, open-label study switch regimens...
BackgroundTwice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy preexposure prophylaxis (PrEP) men, transgender women, and gender-nonbinary persons is unclear.MethodsIn this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants a 2:1 ratio receive every 26 weeks or daily oral emtricitabine–tenofovir disoproxil fumarate (F/TDF). primary analysis compared the incidence...
Abstract Clonal expansions occur in the persistent HIV reservoir as shown by duplication of proviral integration sites. However, source proliferation HIV-infected cells remains unclear. Here, we analyze TCR repertoire single harboring translation-competent proviruses longitudinal samples from eight individuals on antiretroviral therapy (ART). When compared to uninfected cells, is heavily biased: expanded clonotypes are present all individuals, account for majority and often maintained over...
We previously demonstrated superior efficacy and safety advantages in HIV-infected, virologically suppressed adults switched to a regimen containing tenofovir alafenamide (TAF) as compared with those remaining on disoproxil fumarate (TDF) through week 48. now report long-term data 96. In this randomized, active-controlled, multicenter, open-label, noninferiority trial (ClinicalTrials.gov No. NCT01815736), we randomized (HIV-1 RNA <50 copies/ml) (2:1) receive once-daily, single-tablet...
Toll-like receptor 7 (TLR7) agonists, in combination with other therapies, can induce sustained control of simian-human immunodeficiency virus (SHIV) or simian (SIV) nonhuman primates. Here, we report the results a randomized, double-blind, placebo-controlled phase 1b clinical trial an oral TLR7 agonist, vesatolimod, HIV-1-infected controllers on antiretroviral therapy (ART). We randomized participants 2:1 to receive vesatolimod (n = 17) placebo 8) once every week for total 10 doses while...
Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial.In phase 3 MOVe-OUT, non-hospitalized at-risk adults with mild-to-moderate were randomized receive molnupiravir 800 mg or placebo twice daily 5 days. identified based on prior/concomitant medications and/or medical history. All-cause hospitalization/death,...
Most humans have pre-existing immunity to influenza viruses. In this study, volunteers (ages of 18-85 years) were vaccinated with split, inactivated Fluzone™ vaccine in four consecutive seasons from 2013 2016 seasons. The impact repeated vaccination on breadth and durability antibodies was assessed as a result strain changes. Total IgG anti-hemagglutinin (HA) binding hemagglutination-inhibition (HAI) activity increased all age groups against both A HA components the post-vaccination (day...
The Phase III VIKING-3 study demonstrated that dolutegravir (DTG) 50 mg twice daily was efficacious in antiretroviral therapy (ART)-experienced subjects harbouring raltegravir- and/or elvitegravir-resistant HIV-1. VIKING-4 (ING116529) included a placebo-controlled 7-day monotherapy phase to demonstrate short-term antiviral activity attributable DTG.VIKING-4 is randomized, double-blind therapy-experienced adults with integrase inhibitor (INI)-resistant virus randomized DTG or placebo while...
Abstract Background Treatment with vesatolimod, an investigational, oral, toll-like receptor 7 (TLR7) agonist, leads to sustained viral remission in some non-human primates when combined anti-envelope antibodies or therapeutic vaccines. We report results of a Phase Ib study evaluating safety, pharmacokinetics, and pharmacodynamics vesatolimod adults living human immunodeficiency virus (HIV)–1. Methods In this double-blind, multicenter, placebo-controlled trial, participants on antiretroviral...
Objectives: Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance baseline hepatitis B virus (HBV) co-infection. We present feasibility efficacy DTG/3TC newly diagnosed individuals setting. Design: The single-arm STAT study evaluated US Methods: Eligible adults initiated 14 days or less after HIV-1 diagnosis without availability...